NuVasive (NUVA +13%) moves up after beating on its Q3 bottom and top line numbers today. The...

NuVasive (NUVA+13%) moves up after beating on its Q3 bottom and top line numbers today. The company lowers guidance going forward, now expecting FY12 revenue of between $601M to $606M on earnings of $0.88 to $0.90 per share. However, the company also noted that it's aggressively moving to replenish its diminished salesforce that led to flat third-quarter sales growth in its spinal division.